Processa Pharmaceuticals completed its acquisition of Vidya Therapeutics via a stock-for-stock merger, issuing approximately 558,398 shares of common stock and 142,744.1 Series A Preferred Stock to Vidya shareholders. Concurrently, Processa raised approximately $200 million in a private placement by selling 163,774.679 shares of Series A Preferred Stock at an implied conversion price of $1.22119 per share. The transaction results in former Vidya equityholders holding roughly 46% and new investors holding approximately 52.6% of the combined company's fully diluted common stock, while pre-transaction Processa shareholders retain about 0.9%. Additionally, Processa terminated its license agreement for PCS6422 with Elion Oncology in a settlement requiring a $650,000 payment and granting Elion a 7.5% equity stake in any future entity spun out from specific legacy assets. Sheila Gujrathi was appointed to the board as part of the merger integration. Processa Pharmaceuticals is a clinical-stage pharmaceutical company developing innovative drug candidates for immune-mediated diseases.